RT Journal Article
SR Electronic
T1 Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.09.20228197
DO 10.1101/2020.11.09.20228197
A1 Bettiol, Alessandra
A1 Sinico, Renato Alberto
A1 Schiavon, Franco
A1 Monti, Sara
A1 Bozzolo, Enrica Paola
A1 Franceschini, Franco
A1 Govoni, Marcello
A1 Lunardi, Claudio
A1 Guida, Giuseppe
A1 Lopalco, Giuseppe
A1 Paolazzi, Giuseppe
A1 Vacca, Angelo
A1 Gregorini, Gina
A1 Leccese, Pietro
A1 Piga, Matteo
A1 Conti, Fabrizio
A1 Fraticelli, Paolo
A1 Quartuccio, Luca
A1 Alberici, Federico
A1 Salvarani, Carlo
A1 Bettio, Silvano
A1 Negrini, Simone
A1 Selmi, Carlo
A1 Sciascia, Savino
A1 Moroni, Gabriella
A1 Colla, Loredana
A1 Manno, Carlo
A1 Urban, Maria Letizia
A1 Vannacci, Alfredo
A1 Pozzi, Maria Rosa
A1 Fabbrini, Paolo
A1 Polti, Stefano
A1 Felicetti, Mara
A1 Marchi, Maria Rita
A1 Padoan, Roberto
A1 Delvino, Paolo
A1 Caporali, Roberto
A1 Montecucco, Carlomaurizio
A1 Dagna, Lorenzo
A1 Cariddi, Adriana
A1 Toniati, Paola
A1 Tamanini, Silvia
A1 Furini, Federica
A1 Bortoluzzi, Alessandra
A1 Tinazzi, Elisa
A1 Delfino, Lorenzo
A1 Badiu, Iuliana
A1 Rolla, Giovanni
A1 Venerito, Vincenzo
A1 Iannone, Florenzo
A1 Berti, Alvise
A1 Bortolotti, Roberto
A1 Racanelli, Vito
A1 Jeannin, Guido
A1 Padula, Angela
A1 Cauli, Alberto
A1 Priori, Roberta
A1 Gabrielli, Armando
A1 Bond, Milena
A1 Tedesco, Martina
A1 Pazzola, Giulia
A1 Tomietto, Paola
A1 Pellecchio, Marco
A1 Marvisi, Chiara
A1 Maritati, Federica
A1 Palmisano, Alessandra
A1 Dejaco, Christian
A1 Willeit, Johann
A1 Kiechl, Stefan
A1 Olivotto, Iacopo
A1 Willeit, Peter
A1 Prisco, Domenico
A1 Vaglio, Augusto
A1 Emmi, Giacomo
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/11/12/2020.11.09.20228197.abstract
AB Background and objective Systemic small vessel vasculitides carry an increased risk of acute arterial and venous thromboembolic events (AVTE); however, this risk has not been systematically explored in Eosinophilic Granulomatosis with Polyangiitis (EGPA).This study assessed the occurrence and main risk factors of AVTE among EGPA patients as compared to the general community from the population-based Bruneck cohort.Methods We conducted a retrospective multicenter cohort study on 573 EGPA patients. Clinical and serological data were collected at diagnosis. Occurrence of AVTE and time to the first AVTE after EGPA diagnosis were recorded. Age-standardized event rate (SER) of AVTE as compared to the reference cohort was assessed. Cox regression was applied to identify AVTE predictors.Results 129 EGPA patients (22.5%) had AVTE, considered as potentially life-threatening in 55.8%. Seventy patients experienced an AVTE prior to diagnosis (of whom 58.6% in the two years before diagnosis) and 75 following EGPA diagnosis, of whom 56% in the two subsequent years. The SER of AVTE as compared to the reference cohort was 2.10 (95% CI 1.67-2.63). This risk was particularly increased in patients with history of AVTE and with a Birmingham Vasculitis Activity Score ≥20 at diagnosis. Patients receiving immunosuppression within 2 months of diagnosis were at lower risk, while antiplatelet or anticoagulant treatment did not confer measurable benefit.Conclusion EGPA is associated with AVTE in approximately one quarter of patients, particularly around diagnosis. Immunosuppressants seemed to exert a protective effect, while anticoagulant and antiplatelet agents did not.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a retrospective observational studyFunding StatementThis study was not funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in compliance with the Declaration of Helsinki and approved by the Ethic Committee of the University Hospital Careggi, Florence, Italy (Approval number 12804/CAM_BIO).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified participant data are available upon reasonable request, to be sent by email to the corresponding author.